Esmo 2020 – double win complicates the gastric cancer picture
Bristol Myers Squibb and Merck & Co hail front-line successes, but histology and biomarker status will remain live issues for doctors.
Esmo 2020 puts Opdivo and Cabometyx back in the game
Full data from the Checkmate-9ER trial suggest a new combo to match Merck & Co’s Keytruda plus Inlyta in first-line renal cancer.
Diabetes prevention signal emerges for Farxiga
SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?
The bladder cancer pendulum swings towards Bavencio
As Merck & Co’s Keynote-361 study fails, attention turns to Bavencio’s Asco late-breaker and the potential of Padcev.
Asco 2020 – after Tecentriq’s liver win the spotlight falls on Merck and Astra
Roche secures a front-line liver cancer label, but rival data at Asco show that the competition isn’t resting on its laurels.
